{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:40:07Z","timestamp":1793742007855,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA252940"],"award-info":[{"award-number":["R01CA252940"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA251956"],"award-info":[{"award-number":["R50CA251956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA252940"],"award-info":[{"award-number":["R01CA252940"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Landry Cancer Biology Consortium, IBM Research"},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI007529"],"award-info":[{"award-number":["T32 AI007529"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41591-022-01959-0","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T12:07:07Z","timestamp":1662984427000},"page":"1848-1859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":283,"title":["Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-181X","authenticated-orcid":false,"given":"Katie","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyen H.","family":"Gohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M. E.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Katsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-5694","authenticated-orcid":false,"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Southard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-0296","authenticated-orcid":false,"given":"Michael C.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahn","family":"Rhrissorrakrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-7642","authenticated-orcid":false,"given":"Filippo","family":"Utro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-2294","authenticated-orcid":false,"given":"Chaya","family":"Levovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel A.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Slowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-6337","authenticated-orcid":false,"given":"Brian P.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-5856","authenticated-orcid":false,"given":"Kenneth J.","family":"Livak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-5074","authenticated-orcid":false,"given":"Laxmi","family":"Parida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1959_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1959_CR2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1959_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"1959_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135, 597\u2013609 (2020).","journal-title":"Blood"},{"key":"1959_CR5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"1959_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"1959_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1959_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1959_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085 (2021).","journal-title":"Blood"},{"key":"1959_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"1959_CR11","doi-asserted-by":"crossref","unstructured":"Squair, J. W. et al. Confronting false discoveries in single-cell differential expression. Nat. Commun. 12, 5692 (2021).","DOI":"10.1038\/s41467-021-25960-2"},{"key":"1959_CR12","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs, A. C. et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-Seq. Mol. Ther. 28, 2577\u20132592 (2020).","journal-title":"Mol. Ther."},{"key":"1959_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"1959_CR14","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"1959_CR15","doi-asserted-by":"publisher","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"SE Lindner","year":"2020","unstructured":"Lindner, S. E., Johnson, S. M., Brown, C. E. & Wang, L. D. Chimeric antigen receptor signaling: functional consequences and design implications. Sci. Adv. 6, eaaz3223 (2020).","journal-title":"Sci. Adv."},{"key":"1959_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-18-0664","volume":"7","author":"B Yigit","year":"2019","unstructured":"Yigit, B. et al. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunol. Res. 7, 1485\u20131496 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1959_CR17","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat. Commun. 12, 409 (2021).","DOI":"10.1038\/s41467-020-20696-x"},{"key":"1959_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41423-019-0237-x","volume":"17","author":"D Yang","year":"2019","unstructured":"Yang, D. et al. ZBP1 mediates interferon-induced necroptosis. Cell. Mol. Immunol. 17, 356\u2013368 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"1959_CR19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3389\/fimmu.2017.01809","volume":"8","author":"Y Zhan","year":"2017","unstructured":"Zhan, Y., Carrington, E. M., Zhang, Y., Heinzel, S. & Lew, A. M. Life and death of activated T cells: how are they different from na\u00efve T cells? Front. Immunol. 8, 1809 (2017).","journal-title":"Front. Immunol."},{"key":"1959_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995 (2021).","journal-title":"Nat. Immunol."},{"key":"1959_CR21","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D. C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095\u20132113 (2015).","journal-title":"J. Exp. Med."},{"key":"1959_CR22","doi-asserted-by":"crossref","unstructured":"B\u00fcttner, M., Ostner, J., M\u00fcller, C. L., Theis, F. J. & Schubert, B. scCODA is a Bayesian model for compositional single-cell data analysis. Nat. Commun. 12, 6876 (2021).","DOI":"10.1038\/s41467-021-27150-6"},{"key":"1959_CR23","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"1959_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"1959_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature11897","volume":"494","author":"R Kafri","year":"2013","unstructured":"Kafri, R. et al. Dynamics extracted from fixed cells reveal feedback linking cell growth to cell cycle. Nature 494, 480\u2013483 (2013).","journal-title":"Nature"},{"key":"1959_CR26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1959_CR27","doi-asserted-by":"publisher","unstructured":"Talleur, A. et al. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2021006293 (2022).","DOI":"10.1182\/bloodadvances.2021006293"},{"key":"1959_CR28","doi-asserted-by":"publisher","unstructured":"Monfrini, C. et al. Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0164 (2022).","DOI":"10.1158\/1078-0432.CCR-22-0164"},{"key":"1959_CR29","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3389\/fimmu.2018.02692","volume":"9","author":"MD Martin","year":"2018","unstructured":"Martin, M. D. & Badovinac, V. P. Defining memory CD8 T cell. Front. Immunol. 9, 2692 (2018).","journal-title":"Front. Immunol."},{"key":"1959_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"1959_CR31","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","volume":"71","author":"JC Lee","year":"2011","unstructured":"Lee, J. C. et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71, 2871\u20132881 (2011).","journal-title":"Cancer Res."},{"key":"1959_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","volume":"64","author":"S Todo","year":"2016","unstructured":"Todo, S. et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology 64, 632\u2013643 (2016).","journal-title":"Hepatology"},{"key":"1959_CR33","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14415","volume":"17","author":"S Chandran","year":"2017","unstructured":"Chandran, S. et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants. Am. J. Transpl. 17, 2945\u20132954 (2017).","journal-title":"Am. J. Transpl."},{"key":"1959_CR34","doi-asserted-by":"publisher","first-page":"e126194","DOI":"10.1172\/jci.insight.126194","volume":"5","author":"AC Boroughs","year":"2019","unstructured":"Boroughs, A. C. et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5, e126194 (2019).","journal-title":"JCI Insight"},{"key":"1959_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1959_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"1959_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1959_CR38","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1959_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","volume":"19","author":"CE Brown","year":"2019","unstructured":"Brown, C. E. & Mackall, C. L. CAR T cell therapy: inroads to response and resistance. Nat. Rev. Immunol. 19, 73\u201374 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1959_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1959_CR41","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1007\/s12325-020-01397-9","volume":"37","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible? Adv. Ther. 37, 3040\u20133058 (2020).","journal-title":"Adv. Ther."},{"key":"1959_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323\u2013335 (2021).","journal-title":"Blood"},{"key":"1959_CR43","doi-asserted-by":"publisher","first-page":"e000286","DOI":"10.1136\/jitc-2019-000286","volume":"8","author":"BA Derman","year":"2020","unstructured":"Derman, B. A. et al. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J. Immunother. Cancer 8, e000286 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1959_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.intimp.2013.02.001","volume":"16","author":"K Golab","year":"2013","unstructured":"Golab, K. et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int. Immunopharmacol. 16, 371\u2013375 (2013).","journal-title":"Int. Immunopharmacol."},{"key":"1959_CR45","doi-asserted-by":"publisher","first-page":"e0145763","DOI":"10.1371\/journal.pone.0145763","volume":"10","author":"M Florek","year":"2015","unstructured":"Florek, M. et al. Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease. PLoS ONE 10, e0145763 (2015).","journal-title":"PLoS ONE"},{"key":"1959_CR46","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.18632\/oncotarget.23887","volume":"9","author":"K Go\u0142\u0105b","year":"2018","unstructured":"Go\u0142\u0105b, K. et al. Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype. Oncotarget 9, 9728\u20139740 (2018).","journal-title":"Oncotarget"},{"key":"1959_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1959_CR48","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1959_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1959_CR50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1148\/rg.335125214","volume":"33","author":"T Tirkes","year":"2013","unstructured":"Tirkes, T. et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 33, 1323\u20131341 (2013).","journal-title":"Radiographics"},{"key":"1959_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"1959_CR52","unstructured":"June, C. H., Levine, B. L., Porter, D. L., Kalos, M. D. & Milone, M. C. Use of chimeric antigen receptor-modified t cells to treat cancer. European Patent EP3214091B1 (2017)."},{"key":"1959_CR53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"1959_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"1959_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"1959_CR56","doi-asserted-by":"crossref","unstructured":"Ilya, K. N. et al. Fast sensitive and accurate integration of single-cell data with Harmony. Nat. Methods. 16, 1289\u20131296 (2019).","DOI":"10.1038\/s41592-019-0619-0"},{"key":"1959_CR57","unstructured":"Pachter, L. Models for transcript quantification from RNA-Seq. Preprint at https:\/\/arxiv.org\/abs\/1104.3889 (2011)."},{"key":"1959_CR58","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1038\/s41598-019-41695-z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019).","journal-title":"Sci. Rep."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01959-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01959-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01959-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T21:04:41Z","timestamp":1666386281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01959-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1959"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01959-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.04.22273422","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.H. is a consultant for MorphoSys. C.J.W. holds equity in BioNTech Inc. and receives research funding from Pharmacyclics. S.H.G. holds patents related to adoptive cell therapies, held by University College London and Novalgen Limited. S.H.G. provides consultancy to Novalgen Ltd. G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER and SignatureAnalyzer-GPU. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. M.V.M., M.B.L. and R.C.L. are inventors on patents related to adoptive cell therapies, held by MGH. M.V.M. is also an inventor on patents related to CAR-T cell therapies held by the University of Pennsylvania (some licensed to Novartis). M.V.M. is on the Board of Directors of 2SeventyBio, and holds equity in TCR2, Century Therapeutics, Oncternal and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}